Updated:
Intarcia Therapeutics
Intarcia Therapeutics is a Boston-based company founded in 1997. It focuses on developing therapies for diabetes management. The company has secured $1.46...
Intarcia Therapeutics
Intarcia Therapeutics is a Boston-based company founded in 1997. It focuses on developing therapies for diabetes management. The company has secured $1.46 billion in total funding.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Sector focus
Frequently asked questions
What was Intarcia Therapeutics' lead product candidate?
Intarcia's lead product was ITCA 650, a once-yearly subdermal mini-pump delivering exenatide—a GLP-1 receptor agonist—for type 2 diabetes. It demonstrated non-inferiority to daily injections in Phase III trials but failed FDA approval due to manufacturing quality concerns (per the FDA, 2017).
Why did the FDA reject Intarcia's application?
The FDA issued two Complete Response Letters—in 2017 and 2020—citing insufficient evidence of manufacturing quality, specifically relating to stability and sterility of the implantable device. No efficacy or safety concerns with the drug itself were noted (per the FDA's official CRLs, 2017, 2020).
Who acquired Intarcia's assets after its bankruptcy?
Deerfield Management, a healthcare investment firm and Intarcia's secured lender, acquired the company's assets for approximately $150 million through a credit bid in 2020 (per FiercePharma, 2020). Deerfield has not publicly disclosed plans for the Medici Drug Delivery System since.
What is the Medici Drug Delivery System?
The Medici Drug Delivery System is a matchstick-sized osmotic mini-pump implanted under the skin that delivers a steady, continuous dose of a therapeutic agent over 12 months. Developed by Intarcia, it was designed to improve adherence for chronic diseases requiring daily medication (per Intarcia's SEC filings, 2015).
What other therapeutic areas could the Medici platform target?
Beyond diabetes, the Medici platform could theoretically be applied to HIV pre-exposure prophylaxis, opioid-use disorder, cardiovascular disease, and metabolic conditions. The technology enables zero-pill adherence for chronic diseases where daily oral therapy is a barrier. No new clinical programs have been announced since Intarcia's bankruptcy.
How much capital did Intarcia raise before its bankruptcy?
Intarcia raised nearly $1 billion in equity from institutional investors including New Enterprise Associates, Amgen Ventures, Venrock, and Gallileo Partners, among others (per PitchBook, 2020 archive). The company also borrowed from Deerfield Management and other lenders.
Did Intarcia have operations outside of Boston?
Public records indicate Intarcia was headquartered in Boston, MA. No additional offices have been disclosed. The company's clinical trials were conducted across multiple sites in the United States (per ClinicalTrials.gov, 2017).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: